Business Context and Reporting Period
This Form 8-K is filed by ARTELO BIOSCIENCES, INC. (Nasdaq: ARTL) with a report date of May 11, 2026. The filing addresses the termination of a material definitive agreement regarding an equity offering program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific metrics related to the terminated agreement include:
- Program Capacity: Up to $6,500,000 in aggregate offering price.
- Shares Sold: 50,858 shares of Common Stock.
- Gross Proceeds: $451,526.95 (as of May 11, 2026).
Material Changes
The primary material change is the termination of the At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc., originally dated July 18, 2025. The Company provided notice on May 11, 2026, and the termination is effective May 18, 2026. Consequently, the Company can no longer sell shares under this specific program.
Outlook and Management Commentary
The filing contains no forward-looking guidance, management commentary on future strategy, or discussion of risks and contingencies beyond the execution of the termination. The document is a procedural notification of the agreement's end.
Investor Verification Checklist
- Verify the effective termination date of May 18, 2026, to confirm the cessation of sales under this program.
- Confirm the total gross proceeds of $451,526.95 against the company's cash position in subsequent filings.
- Check for any new equity financing plans or alternative capital raising strategies announced in future reports.
- Review the remaining unsold capacity ($6,048,473.05) to understand the capital gap left by the termination.